Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.

BACKGROUND: In corticosteroid-resistant acute severe ulcerative colitis (ASUC), cyclosporine is frequently used in biologic-exposed patients, but data on maintenance strategies after cyclosporine response remain limited. We aimed to describe 12-month outcomes after a cyclosporine-to-biologic bridge and to explore outcomes according to maintenance therapy. METHODS: This single-center retrospective study screened all patients treated with cyclosporine for ASUC between 2014 and 2024. Patients who responded to cyclosporine and subsequently received vedolizumab or ustekinumab as maintenance therapy were included. The primary endpoint was 12-month colectomy-free survival. Secondary endpoints included steroid-free clinical remission, combined clinical/biological remission, treatment persistence, and adverse events. Comparisons between maintenance therapies were exploratory. RESULTS: Among 67 patients treated with cyclosporine for ASUC, 44 responders were included (35 vedolizumab, 9 ustekinumab, and 96% biologic-exposed). Median follow-up was 39 months. Maintenance therapy was initiated a median of 7 days after cyclosporine initiation. Overall 12-month colectomy-free survival was 73% (95% CI, 61-88). In exploratory analyses, colectomy-free survival appeared lower with ustekinumab than with vedolizumab (47% vs 79%, log-rank P = .03). At 12 months, overall treatment persistence was 46% and combined clinical/biological remission was 34%. Adverse events were predominantly renal or neurological. CONCLUSIONS: In this predominantly biologic-exposed, cyclosporine-responsive ASUC cohort, a bridge to vedolizumab or ustekinumab was associated with 73% colectomy-free survival at 12 months and an acceptable safety profile. Comparisons between maintenance therapies remain exploratory.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/ibd/izag222
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.

Xavier Tréton, Marc Harb, Thomas Bazin, Alexandre Nuzzo et al.
PubMed
Inflammatory Bowel Disease
article

Cyclosporine-to-biologic bridging in biologic-exposed acute severe ulcerative colitis: a single-center retrospective cohort study.

Xavier Tréton, Marc Harb, Thomas Bazin, Alexandre Nuzzo, Carmen Stefanescu, Francisca Joly, Lara Ribeiro, Yoram Bouhnik, Teodor Berea
article en

Abstract

BACKGROUND: In corticosteroid-resistant acute severe ulcerative colitis (ASUC), cyclosporine is frequently used in biologic-exposed patients, but data on maintenance strategies after cyclosporine response remain limited. We aimed to describe 12-month outcomes after a cyclosporine-to-biologic bridge and to explore outcomes according to maintenance therapy. METHODS: This single-center retrospective study screened all patients treated with cyclosporine for ASUC between 2014 and 2024. Patients who responded to cyclosporine and subsequently received vedolizumab or ustekinumab as maintenance therapy were included. The primary endpoint was 12-month colectomy-free survival. Secondary endpoints included steroid-free clinical remission, combined clinical/biological remission, treatment persistence, and adverse events. Comparisons between maintenance therapies were exploratory. RESULTS: Among 67 patients treated with cyclosporine for ASUC, 44 responders were included (35 vedolizumab, 9 ustekinumab, and 96% biologic-exposed). Median follow-up was 39 months. Maintenance therapy was initiated a median of 7 days after cyclosporine initiation. Overall 12-month colectomy-free survival was 73% (95% CI, 61-88). In exploratory analyses, colectomy-free survival appeared lower with ustekinumab than with vedolizumab (47% vs 79%, log-rank P = .03). At 12 months, overall treatment persistence was 46% and combined clinical/biological remission was 34%. Adverse events were predominantly renal or neurological. CONCLUSIONS: In this predominantly biologic-exposed, cyclosporine-responsive ASUC cohort, a bridge to vedolizumab or ustekinumab was associated with 73% colectomy-free survival at 12 months and an acceptable safety profile. Comparisons between maintenance therapies remain exploratory.

PubMed
Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris Cité (FR), Université Paris-Saclay (FR), Hôpital Beaujon (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre de Recherche sur l'Inflammation (FR), Laboratoire de Recherche Vasculaire Translationnelle (FR)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon